In this presentation from the 18th European Congress: Perspectives in Lung Cancer, Dr. Paul Van Schil arguest that trimodality therapy is the optimal approach for stage III non-small cell lung cancer (NSCLC).
Earn CME Credit for a related activity: http://elc.imedex.com/ELC/Specialty-Search.aspx?search=Lung
© 2017 Imedex, LLC.
Advertisement